## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 10.0% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($118.57)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. What's Happening With French Biotech Abivax Stock On Wednesday?**
- Source: Benzinga | 20251210T180903 | Bullish | Relevance: 99%
-  Abivax SA's stock is trading higher on Wednesday due to market rumors of a potential takeover by U.S. pharma giant Eli Lilly and Co. The company's stock has surged over 1,500% in the past six months, driven significantly by positive Phase 3 trial results for its ulcerative colitis treatment, obefazimod. Eli Lilly has also been speculated to be preparing for other major acquisitions, including Viking Therapeutics Inc.

**2. Abivax Stock: What Lies Ahead?**
- Source: StocksToTrade | 20251210T020903 | Bullish | Relevance: 99%
-  Abivax SA stock is trending up due to positive sentiment from promising Phase 3 trial results for obefazimod in ulcerative colitis and upcoming Phase 2b data in Crohn’s disease. Analysts have issued a "Buy" rating with a target price of $140, highlighting the drug's unique mechanism and broad immune effects. The company reported strong financial results, including $812M in revenue and $468M in Free Cash Flow, positioning it well for future growth driven by these significant clinical milestones.

**3. Abivax (NASDAQ:ABVX) Reaches New 52-Week High - Should You Buy?**
- Source: MarketBeat | 20251210T160903 | Bullish | Relevance: 99%
- Abivax (NASDAQ:ABVX) hit a new 52-week high of $137.00, trading strongly at $134.699 with a $10.62 billion market cap. Wall Street analysts maintain a "Moderate Buy" rating with an average $123.00 price target, with Guggenheim raising its objective to $150. The biotech company is developing obefazimod for ulcerative colitis and has seen increased institutional holdings despite negative EPS forecasts.

**4. Is Obefazimod’s Phase 3 UC Success Reshaping The Investment Case For ABIVAX (ENXTPA:ABVX)?**
- Source: Simply Wall Street | 20251210T030903 | Somewhat-Bullish | Relevance: 98%
-  Abivax's lead candidate, obefazimod, has shown statistically significant success in Phase 3 trials for ulcerative colitis, leading the company to plan a U.S. regulatory submission by late 2026. While these results strengthen the short-term outlook and have driven a significant share price increase, the company remains clinical-stage and loss-making, with its investment narrative heavily reliant on regulatory approval and future financing. Investors must weigh the potential for a commercially viable drug against the risks of cash burn, dilution, and negative equity.

**5. Abivax Sees Unusually Large Options Volume (NASDAQ:ABVX)**
- Source: MarketBeat | 20251209T160928 | Bullish | Relevance: 98%
-  Abivax (NASDAQ:ABVX) experienced unusually large options trading volume on Tuesday, with traders purchasing 3,575 call options, an 82% increase over the daily average. This activity comes as analysts have raised price targets and ratings, with a consensus "Moderate Buy" rating and an average target of $123. The clinical-stage biotech is advancing its lead drug obefazimod in Phase 3 trials for ulcerative colitis, and its shares traded up about 5.9% to $121.85 amid the increased interest.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +12.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.5B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -2.4% to 10.0% (+12.4% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (10.0% > 10.0%), caution on chasing. MRS_5 at 8.5% confirms short-term momentum alignment. AM_20 at 12.4% shows strong absolute momentum above own 20MA. Outperforming sector by 12.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.9x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 10.02% (CS: 93) | Strong |
| RSI_14 | 69.8 | Neutral |
| MACD Histogram | 0.32 | Bullish |
| vs SMA20 | 1.124x | Above |
| vs SMA50 | 1.273x | Above |
| vs SMA200 | 2.717x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $133.09
- **Stop Loss:** $118.57 (10.9% risk)
- **Target:** $147.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 95
- **Position Value:** $12,643.55
- **Portfolio %:** 12.64%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*